Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$10 Mln
P/E Ratio
--
P/B Ratio
0.2
Industry P/E
--
Debt to Equity
0.02
ROE
-0.62 %
ROCE
-58.59 %
Div. Yield
0 %
Book Value
3.94
EPS
-3.35
CFO
$-251.52 Mln
EBITDA
$-353.25 Mln
Net Profit
$-319.30 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Hookipa Pharma Inc (HOOK)
| -58.21 | -28.81 | -57.14 | -90.60 | -62.16 | -60.33 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Hookipa Pharma Inc (HOOK)
| -74.90 | 0.00 | -65.24 | -78.99 | -9.32 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.09 | 6,904.81 | -- | 38.11 | |
| 73.12 | 7,574.08 | 58.3 | 23.56 | |
| 60.12 | 11,448.88 | 394.4 | 0.76 | |
| 8.37 | 9,704.70 | -- | -3.24 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation... multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York. Read more
CEO & Director
Mr. Joern Aldag
CEO & Director
Dr. Malte Peters M.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Hookipa Pharma Inc (HOOK) stood at $ 83 Mln as on 31-Dec-24
The share price of Hookipa Pharma Inc (HOOK) is $0.84 (NASDAQ) as of 29-Apr-2025 12:41 EDT. Hookipa Pharma Inc (HOOK) has given a return of -62.16% in the last 3 years.
Hookipa Pharma Inc (HOOK) has a market capitalisation of $ 10 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Hookipa Pharma Inc (HOOK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Hookipa Pharma Inc (HOOK) and enter the required number of quantities and click on buy to purchase the shares of Hookipa Pharma Inc (HOOK).
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
The CEO & director of Mr. Joern Aldag. is Hookipa Pharma Inc (HOOK), and CFO & Sr. VP is Dr. Malte Peters M.D..
There is no promoter pledging in Hookipa Pharma Inc (HOOK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Hookipa Pharma Inc (HOOK) | Ratios |
|---|---|
|
Return on equity(%)
|
-61.68
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-98.99
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Hookipa Pharma Inc (HOOK) was $0 Mln.
$0.04
(
